Thanks, CP. Based on your/Golfho's estimates the DMC could issue an interim report at any time. My research on FDA guidelines for DMCs leads me to expect minimal sharing of data with Peregrine management. Of course, it may be the Sunrise DMC instructions are more liberal.
As to a PR from the first look-in, I fully expect one. I just hope Peregrine will have some data other than enrollment progress to share. By this time I believe the data should give an indication if the Phase III effectiveness mirrors the great numbers we saw in the Phase II. This is what would reassure me that the trial will likely be a success, and not coincidentally we will make money.
GLTA, Paul